Abstract: This invention relates to a fulvic acid and antibiotic combination for use in the treatment of various diseases and conditions. The invention further relates to the use of the combination for the treatment of various diseases and conditions, including bacterial infection. In particular, the bacteria are antibiotic resistant bacteria.

Abstract: A substance for use in the treatment of cancer, includes a compound selected from metallocenyl &bgr;-diketones Mc-CO—CZ1Z2-CO—R. Mc is Fc (ferrocenyl), Rc (ruthenocenyl) or Oc (osmocenyl), R is 11, alkyl or aryl and Z1 and Z2 are H, alkyl, aryl or substituted alkyl, ferrocenyl, the enol forms of the &bgr;-diketones and metal complexes of the &bgr;-diketones of the general formula M(&bgr;-diketonato)A1, M(&bgr;-diketonato)A1A2, M(&bgr;-diketonato)A1B1B2, M(&bgr;-diketonato)B1B2 and M(&bgr;-diketonato)B1B2B3B4. M is Rh or Ir, A1 and A2 are cyclic dienes having 6-8 carbons, or linear alkenes having 2-7 carbons. B1, B2, B3 and B4 are selected from CO, P(R1R2R3), P(OR1)(OR2)(OR3), R4 and X in which R1, R2, R3 and R4 are independently alkyl, phenyl or ferrocenyl, and X is a halide or a pseudohalide.

Abstract: A pharmaceutical composition comprising an oxihumic acid, salt, ester, or derivative thereof as an active ingredient is disclosed. The composition is preferably administered only for stimulating lymphocytes in a human, animal, or bird. It may be used in treating viral and bacterial infections, HIV infections, opportunistic diseases, inflammation, pain and fever, cancer growth, and diseases associated with viral infection and a depressed immune system.

Abstract: Fulvic acid salts, esters or derivatives thereof in pharmaceutical preparations are effective for treating inflammation, acne, exzema or bacterial or fungal or viral infections. These pharmaceutical preparations may be given either orally or topically in the form of a solution, paste, ointment, powder to humans or animals.

Abstract: The invention provides the use of a riminophenazine in the manufacture of a medicament to treat parasitic infections. The riminophenazine may be used for the prophylactic treatments of maleria or for the therapeutic treatment of maleria. A known anti-maleria drug, e.g. chloroquine or mefloquine may be administered as well. The riminophenazine may be a compound of the general formula: ##STR1## wherein: R.sup.1 is selected from hydrogen atoms, halogen atoms, alkyl, alkoxy and trifluoromethyl radicals,R.sub.2 is selected from hydrogen or halogen atoms,R.sup.3 is selected from hydrogen atoms, alkyl, substituted alkyl, cycloalkyl, cycloalkylalkyl, unsubstituted heterocyclic radicals, substituted heterocyclic radicals, unsubstituted heterocyclicalkyl and substituted heterocyclicalkyl radicals.

Abstract: The invention concerns the new use of riminophenazines in the treatment of a patient who has built up, or could build up, resistance to a therapeutically active substance, such as a patient requiring treatment for cancer. The riminophenazine conveniently may be of the general formula (I). ##STR1## R.sup.1 is a hydrogen atom, a halogen atom or a (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, fluoromethoxy or trifluoromethyl radical, R.sup.2 is a hydrogen or halogen atom, R.sup.3 is selected from hydrogen, (C.sub.1 -C.sub.4) alkyl, N,N-dialkylamino alkyl, (C.sub.3 -C.sub.12) cycloalkyl, methylcyclohexyl, hydroxycyclohexyl, cycloalkylmethyl, piperidyl, alkyl substituted piperidyl or N-benzyl-substituted pipperidyl, R.sup.4 is a hydrogen or halogen atom or a (C.sub.1 -C.sub.3) alkyl, (C.sub.1 -C.sub.3) alkoxy, fluoromethoxy or trifluoromethyl radical, and n is 1, 2 or 3. The invention also provides novel riminophenazines of general formula (I), their preparation, and compositions containing them.